Depression is the leading cause of disability globally, and yet the treatment success rate for major depressive disorder has barely improved in decades. Roughly one-third of patients don't achieve remission with first-line treatment — and the STAR*D trial famously showed that figure barely budges with sequential medication trials. What's different in 2026 is that the new approaches aren't just incremental improvements on SSRIs. Ketamine's mechanism was validated and approved. Psilocybin's Phase 3 data has arrived. TMS protocols have become more targeted and faster. For patients who have cycled through multiple antidepressants, this landscape is genuinely different from what existed five years ago.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Major depressive disorder affects over 280 million people worldwide. Approximately 30% of patients don't respond adequately to standard treatments after two or more medication trials — classified as treatment-resistant depression (TRD). In 2026, depression research is experiencing a genuine renaissance: esketamine is approved and being optimized, psilocybin Phase 3 trials are enrolling, accelerated TMS protocols show rapid response in days rather than weeks, and zuranolone — a 14-day oral neuroactive steroid — was approved in 2023. For TRD patients, the trial landscape now offers mechanistically distinct options that didn't exist a generation ago.
ClinicalMetric Analysis
- The FDA's psilocybin CRL was about blinding, and that problem is unsolved. Participants know when they've received psilocybin — the experience is unmistakable. Expectancy effects and the therapeutic relationship with session guides could account for significant portions of the measured MADRS improvement. The FDA's Complete Response Letter to Lykos Therapeutics in 2024 didn't reject the mechanism; it rejected the trial design as inadequate to isolate the drug effect. Until psychedelic researchers develop validated active placebo controls that produce comparable non-specific effects, this methodological hole remains open.
- STAR*D's TRD definition inflated the treatable population. STAR*D defined treatment-resistant depression as failure of two adequate medication trials. But "adequate" was applied generously — many participants received subtherapeutic doses for insufficient durations. Real-world TRD in patients who received genuinely optimized sequential therapies is a smaller, harder population. Psilocybin, esketamine, and SAINT TMS trial results may look different when applied to truly refractory patients versus the broader TRD label.
- Zuranolone's 14-day design is a feature, not a limitation — but requires clinical support to use correctly. The episodic dosing model (14 days on, off, then as needed for recurrence) is actually how antidepressants should ideally work for episodic illness. The problem is that most prescribers and patients are conditioned to think of antidepressants as indefinite daily medications. Without explicit guidance on recurrence detection and re-treatment triggers, zuranolone's time-limited design will be misused — either abandoned prematurely or extended beyond intention.
Ketamine and Esketamine: Rapid Action Through NMDA Antagonism
The central discovery driving ketamine's use in depression is speed: it works within hours, not weeks. The mechanism — blocking NMDA receptors and triggering downstream AMPA receptor activation and BDNF release — is fundamentally different from monoamine-targeting antidepressants, which is why it works in patients who have failed multiple SSRIs, SNRIs, and TCAs.
Esketamine (Spravato, Janssen) — the S-enantiomer of ketamine delivered intranasally — received FDA approval in 2019 for treatment-resistant depression and in 2020 for MDD with acute suicidal ideation. The TRANSFORM Phase 3 program showed significant improvement on MADRS total score at 28 days versus placebo (point difference: −4.1 in TRANSFORM-2, p=0.02), with a subset of patients achieving sustained remission. The intranasal route requires in-clinic supervised administration due to dissociation risk.
Current trials in 2026 are addressing the practical questions: optimal maintenance dosing frequency after initial response (weekly vs. biweekly vs. monthly), whether combining esketamine with a newly initiated oral antidepressant sustains remission better than either alone, and biomarkers — including EEG gamma-band signatures and baseline inflammatory markers — that predict who will respond. IV racemic ketamine infusion programs have expanded dramatically outside clinical trials; researchers are comparing infusion protocols to the approved intranasal product in head-to-head designs.
Psilocybin-Assisted Therapy: Phase 3 Data Arriving
Psilocybin has shown consistently remarkable efficacy in Phase 2 trials for treatment-resistant depression. The COMPASS Pathways COMP360 Phase 2b trial — 233 participants across 10 countries — showed that a single dose of 25 mg psilocybin produced a significant reduction in MADRS score at 3 weeks (difference: −6.6 vs. 1 mg placebo, p=0.004), with 29% achieving response and 24% achieving remission. These are patients who had failed a median of 4–5 prior antidepressant trials.
The COMPASS Phase 3 program (COMP360 Phase 3) is the largest psilocybin trial ever conducted — recruiting patients who have failed at least two adequate antidepressant trials across sites in the US, EU, and Canada. Usona Institute is running parallel Phase 3 trials for MDD. The structure of psilocybin trials is worth understanding before applying: participants receive structured psychological preparation sessions with trained therapists before the drug session, a supervised drug experience lasting 6–8 hours, and integration therapy sessions afterward. It's not a simple pill — it's a therapeutic program built around the pharmacological experience.
Key exclusion criteria across psilocybin trials: personal or first-degree family history of psychosis or bipolar I disorder, current lithium or valproate use (serotonin syndrome risk), cardiovascular disease, and current high-dose SSRI use (which attenuates the psilocybin effect).
New Pharmacological Approaches
Zuranolone (Zurzuvae)
FDA-approved in August 2023, zuranolone is a positive allosteric modulator of GABA-A receptors — a neuroactive steroid taken as a 14-day oral course rather than a chronic daily medication. The LANDSCAPE and SHORELINE trials showed significant antidepressant effect with rapid onset (day 3) and a response rate of approximately 43% at day 15 versus 30% placebo. What's interesting about the mechanism is its relationship to endogenous neurosteroid fluctuations that have been implicated in postpartum depression and perimenstrual mood disorders. Current trials in 2026 are investigating zuranolone in specific populations (perimenopausal women, patients with co-occurring insomnia) and extended-course regimens.
AMPA Receptor Potentiators
Drugs that enhance glutamate signaling via AMPA receptors — a downstream mediator of ketamine's antidepressant effects — without producing dissociation or abuse potential. The goal is ketamine-like mechanism with a more tolerable profile. Several compounds are in Phase 2, including LY3130481 (Eli Lilly) and BIIB104 (Biogen). Early data shows signals of antidepressant activity in treatment-resistant patients, but definitive Phase 3 data is 2–3 years away.
Anti-Inflammatory Approaches for Inflammatory-Subtype Depression
Approximately 30–40% of depressed patients have elevated inflammatory markers — elevated CRP, IL-6, TNF-alpha — and this subgroup responds poorly to monoamine-targeting drugs but may respond to anti-inflammatory interventions. Trials in 2026 are testing this hypothesis with: low-dose naltrexone (microglial modulator), infliximab (anti-TNF, in high-CRP patients specifically), and a celecoxib augmentation strategy. The data is preliminary but the biological hypothesis is compelling enough to drive multiple concurrent trials.
Accelerated TMS: From 6 Weeks to 5 Days
Standard transcranial magnetic stimulation (TMS) for MDD involves 30-minute sessions 5 days per week for 6 weeks — a 36-session protocol that requires significant time commitment. The Stanford Neuromodulation Therapy (SNT) protocol — also called SAINT — delivers multiple sessions per day over just 5 days, using intermittent theta burst stimulation (iTBS) targeted to the subgenual anterior cingulate cortex using individual fMRI-guided targeting.
The Phase 2 SAINT trial showed a 78.6% remission rate in TRD patients (vs. 13.6% sham) at 4 weeks — extraordinary numbers that attracted significant attention. A larger Phase 3 replication (SAINT-2) is underway across multiple centers, and the question of whether individual fMRI targeting is necessary or whether a standardized target provides comparable results is being addressed directly. Deep TMS (dTMS, BrainsWay H-coil) and theta burst stimulation are also in active comparative Phase 3 trials.
Who Qualifies for Depression Trials
Most depression trials require a formal DSM-5 diagnosis confirmed by a structured clinical interview (MINI, SCID), a minimum severity score at screening (MADRS ≥20 or HDRS ≥17 or PHQ-9 ≥10), and a specific treatment history. TRD trials typically require documentation of failure of at least 2 antidepressants at adequate dose (≥6 weeks) and duration during the current episode.
Common exclusion criteria: active suicidal ideation with a plan or recent attempt, psychotic features, bipolar I disorder (lifetime), active substance use disorder, and certain medical conditions that affect interpretation of safety data. For ketamine and psilocybin trials specifically, cardiovascular contraindications are screened carefully given hemodynamic effects during the drug session. Washout periods for current antidepressants range from 5 half-lives to 5 weeks depending on the drug and the trial protocol.